ClinicalTrials.gg
RecruitingNCT06727487ENBIUpdated Dec 11, 2024

OvS Breast: Ovarian Suppression in Breast Cancer Interventions

An interventional study of Basic recommendations and Physical exercise in Breast Neoplasms, sponsored by Universidad Pontificia Comillas. Recruiting at 2 sites in Spain. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2024-12-11.

Sponsored by Universidad Pontificia Comillas · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 905 studies in Breast Neoplasms with a site in Spain — 164 open to participants now, 285 under way, 84 of them phase 3. Breast Neoplasms · Spain.

Planned enrollment
718th of 805
30 · median 151
Started
2024
with 54 others
No phase
146 of 905
51 open now
Primary completion
2025-04
later than 54 of 284 live
Registered
751st of 905
by date

Among the 905 studies in Breast Neoplasms with a site in Spain, this one is the 718th largest by planned enrollment of the 805 interventional ones that give a count, is one of 55 that started in 2024, is one of 146 with no phase, reaches primary completion later than 54 of the 284 other live ones, and was the 751st registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

164 of the 905 studies in Breast Neoplasms with a site in Spain are open now. Recruiting first, the newest first:

159 more — sign in →

All 164 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 905 studies in Breast Neoplasms with a site in Spain, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare a combined intervention based on physical exercise, nutritional control, and individualized psycho-oncological support can achieve weight control and maintain adequate body composition in premenopausal women with localized BC with ER and/or PR expression who receive aLHRH in combination with TAM or AI as part of adjuvant treatment.

The study's primary objectives are to evaluate the impact of the combined intervention on weight reduction and favorable modification of body composition in terms of reduction in body fat and increase in lean mass.

The secondary objectives aim to evaluate the impact of the combined intervention program on CRF, heart rate (HR), capillary lactate levels, upper and lower body strength, physical functionality, and patient-reported outcomes (PROs). (exercise level, asthenia, self-perception, anxiety and depression), blood count and biochemistry values that could be modified, nutritional situation, and side effects of treatments.

Read the detailed description

Breast cancer (BC) is the most common and incident neoplasia in women in Spain and is the third cause of cancer death after lung and colorectal cancer. In turn, BC with hormone receptor expression is the most common and corresponds to approximately 75% of BC cases.

Suppression of ovarian function combined with endocrine treatment (gonadotropin-releasing hormone analog (LHRH) associated with tamoxifen (TAM) or aromatase inhibitors (AI)) has demonstrated a benefit in terms of relapse-free survival (PFS) and overall survival (OS) in premenopausal women diagnosed with localized BC with estrogen receptor (ER) and progesterone (PR) expression. This benefit is mainly focused on patients diagnosed at younger ages (under 45 years) and those with other clinical-pathological factors that imply an exceptionally high risk of relapse.

Despite their benefits, the adverse effects of these treatments are not trivial and include significant toxicities in the cardiorespiratory, metabolic, sexual, and emotional spheres. Metabolic alterations include unfavorable changes in body composition with increases in the percentage of fat and weight that can be observed already in the first months of treatment, which in turn is directly related to an increased risk of BC relapse in these patients.

Changes in body composition with increased fat and decreased muscle mass lead to a pro-inflammatory and dysfunctional state of the immune system, which in turn has been linked to the development of cardiovascular diseases and a worse oncological prognosis.

Scientific evidence suggests that nutritional interventions combined with physical exercise and adapted to physiological needs, the baseline physical level, and the adverse effects derived from the treatments can be safe and effective in achieving adequate weight control and body composition. All of this would favor restoring the immune system's functionality and increasing patients' cardiorespiratory capacity (CRF), which could ultimately translate into a better quality of life.

However, adherence to these programs is low for many reasons, and psycho-oncological support with behavioral interventions could favor adherence to them and stimulate changes in patients' lifestyles.

Despite the evidence, there is no scientific consensus regarding the dosage of exercise and the type of nutritional intervention that should be applied to patients with BC whose treatment includes suppression of ovarian function. In this sense, these interventions should be individualized and adapted to the characteristics of each patient, taking into account all the factors that could affect adherence to these programs.

This project has been designed as a pilot study to evaluate the impact of an intervention program incorporating physical exercise and nutritional control strategies adapted to the baseline situation and level of physical fitness of each premenopausal patient with localized BC on adjuvant treatment with ovarian function suppression.

HYPOTHESIS AND OBJECTIVES: combined intervention based on physical exercise, nutritional control, and individualized psycho-oncological support can achieve weight control and maintain adequate body composition in premenopausal women with localized BC with ER and PR expression who receive aLHRH in combination with TAM or AI as part of their adjuvant treatment.

The study's primary objectives are to evaluate the impact of the combined intervention on weight reduction and favorable modification of body composition in terms of reduction of body fat and increase of lean mass.

The secondary objectives aim to evaluate the impact of the combined intervention program on CRF, heart rate (HR), capillary lactate levels, upper and lower body strength, physical functionality, patient-reported outcomes (PROs) (exercise level, asthenia, self-perception, anxiety, and depression), blood count and biochemistry values that could be modified, nutritional status and side effects of the treatments.

The exploratory objectives, on the other hand, consist of evaluating the impact of the combined intervention on the levels of pro-inflammatory substances (C-reactive protein (CRP) and TNF-alpha) and anti-inflammatory substances (adiponectin) as well as on the levels of oncostatin M, a myokine whose release increases with exercise and seems to stimulate apoptosis and interfere with exercise.

03

Conditions studied

  • Breast Neoplasms

Keywords

  • Physical Exercise
  • Nutritional advice
  • Psico-oncological support
  • Patient Report Outcomes
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women who have reached the age of majority and up to 45 years of age.
  • Premenopausal status is defined clinically as a patient who maintains menstruation prior to the start of chemotherapy treatment if this has taken place.
  • Confirmed histological diagnosis of infiltrating breast carcinoma with expression of ER and/or RP stage I to III.
  • Loco-regional treatment with surgery and radiotherapy, if any, completed.
  • treatment with drugs that suppress ovarian function (aLHRH) is ongoing and expected to be maintained for at least 4 months at the beginning of the study.
  • Functional status according to the (ECOG) scale 0-1.
  • Ability to understand and agree to the in writing.

Exclusion criteria

Exclusion Criteria:

  • Presence of medical to perform physical exercise.
  • Presence of any of the American Thoracic Society (ATS) criteria to perform a cardiovascular capacity test.
  • Presence of active neoplastic disease: breast cancer or other active tumor diseases.
  • Pregnancy or breastfeeding.
  • Alcohol or other drug abuse (excluding smoking).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    Group 1, control

    Group 1/Control: patients will receive the basic recommendations on healthy lifestyle habits indicated by the World Health Organization (WHO) through audiovisual material that they will receive via email. An explanatory video and a document with WHO guidelines will be included (https://apps.who.int/iris/bitstream/handle/10665/337004/9789240014817-spa.pdf).

    Behavioral: Basic recommendations

  • Experimental
    Group 2, experimental

    Group 2/ Exercise, nutrition, and psycho-oncological support: patients will carry out a cardiovascular and strength exercise program of moderate-high intensity at the facilities of the Exercise and Cancer Center organized in sessions of 60 to 75 minutes in duration, with a frequency of 2 days/week for 12 weeks; In addition, 3 sessions of nutritional counseling and 3 sessions of psycho-oncological intervention will be developed.

    Behavioral: Physical exercise · Behavioral: Nutritional advice · Behavioral: Psycho-oncological support

Interventions

  • BehavioralBasic recommendations

    Daily basis activity counseling by WHO recommendations

  • BehavioralPhysical exercise

    A complete program of active physical exercise of medium and high intensity

  • BehavioralNutritional advice

    A complete program of nutritional counseling

  • BehavioralPsycho-oncological support

    A program related with a patient Psycho-oncological follow-up

06

What researchers measure

Primary outcomes

  1. Combined intervention evaluation on weight control

    A combined intervention based on physical exercise, nutritional control, and individualized psycho-oncological support can achieve weight control and maintain adequate body composition in premenopausal women with localized breast cancer expressing estrogen receptors and progesterone receptors who receive adjuvant treatment. The psycho-oncological intervention program aims to increase motivation to adhere to the physical exercise program and nutritional recommendations and maintain long-term healthy lifestyle habits.

    Time frame: 1 year

  2. Combined intervention evaluation in body composition

    The variables weight, kilograms, fat mass, lean mass, and extracellular water will be obtained with the Tanita BC-601 Gold scale, including an impedance meter. The height, waist, and hip circumferences will be obtained with a tape measure. These measurements are necessary for calculating the BMI and the waist-high index (measure in centimeters). Weight and height will be combined to report BMI in kg/m\^2 Units of measure: weight in kilograms, height in meters.

    Time frame: 1 year

Secondary outcomes

  1. Improve Quality of Life on Patient Report Outcomes

    To evaluate the impact of the combined intervention program on patient-reported outcomes (PROs) (exercise level , asthenia, self-perception, anxiety and depression). The combination of several validated tests allows us to establish a balanced measure with the multi-professional approaches that care for the patient. Patient Reported Outcomes (PROs): These will be assessed and collected by completing validated questionnaires for this purpose. * Quality of life: EuroQoL-5D questionnaire * Fatigue: FACIT-Fatigue questionnaire * Level of physical activity: International Physical Activity Questionnaire (IPAQ) * Self-perception/self-esteem: Rosemberg Self-Esteem Scale * Anxiety and Depression: Hospital Anxiety and Depression Scale (HADS)

    Time frame: 1 year

  2. Nutritional Status follow-up

    Nutritional status: It will be assessed using the following tools at the beginning, 6 weeks after the start of the intervention and at the end of the 12 weeks.The combination of several validated tests allows us to establish a balanced measure of the specific situation in each patient. * 3-day nutritional record * Predimed Mediterranean diet adherence questionnaire * WCRF/AICR recommendations compliance scale

    Time frame: 1 year

  3. Psycho-oncological assessment

    Psycho-oncological assessment: It will be assessed with the following questionnaires that the patient will complete at the beginning and the end of the 12 weeks of intervention. The combination of several validated tests allows us to establish a measure that relates the emotional state with the variables of physical exercise The PANAS affectivity scale will have an additional intermediate evaluation six weeks after the start of the intervention. * PANAS affectivity scale * Transtheoretical model of change in physical exercise (CMTCEJ) questionnaire. * MOS social support questionnaire

    Time frame: 1 year

  4. Cardiorespiratory Fitness: Evaluation of physical activity performance

    Evaluation of physical activity performance thought: -Cardiorespiratory fitness (CRF): The Bruce test will be evaluated to determine the maximum oxygen consumption (VO2max, milliliters/kilogram/minute). -Cardiac variability (HR at rest and maximum (beats/minute)): It will be measured with an HR receiver before the Bruce test (at rest) and at the time of finishing it (maximum effort)

    Time frame: 1 year

  5. Endurance performance: Evaluation of physical activity performance:

    -Endurance performance (capillary lactate levels (millimoles/liter): They will be evaluated with a lactate analyzer at rest, at the time of finishing it (maximum effort), and two minutes after having finished it.

    Time frame: 1 year

  6. Strength: Evaluation of physical activity performance

    -Strength: It will be evaluated using dynamometry of the upper and lower body, as well as with the squat test and shoulder press with load (kilograms mobilized and repetitions performed).

    Time frame: 1 year

  7. Physical functionality: Evaluation of physical activity performance

    -Physical functionality: It will be measured with the maximum squat test in 30 seconds (number of repetitions) and 6-minute walk (maximum distance in meters that the patient can walk for 6 minutes).

    Time frame: 1 year

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Lang I, Gomez HL, Tondini C, Ciruelos E, Burstein HJ, Bonnefoi HR, Bellet M, Martino S, Geyer CE Jr, Goetz MP, Stearns V, Pinotti G, Puglisi F, Spazzapan S, Climent MA, Pavesi L, Ruhstaller T, Davidson NE, Coleman R, Debled M, Buchholz S, Ingle JN, Winer EP, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Goldhirsch A, Regan MM; SOFT and TEXT Investigators and the International Breast Cancer Study Group. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med. 2018 Jul 12;379(2):122-137. doi: 10.1056/NEJMoa1803164. Epub 2018 Jun 4. PubMed 29863451 ↗
  • Francis PA, Fleming GF, Lang I, Ciruelos EM, Bonnefoi HR, Bellet M, Bernardo A, Climent MA, Martino S, Bermejo B, Burstein HJ, Davidson NE, Geyer CE Jr, Walley BA, Ingle JN, Coleman RE, Muller B, Le Du F, Loibl S, Winer EP, Ruepp B, Loi S, Colleoni M, Coates AS, Gelber RD, Goldhirsch A, Regan MM; SOFT Investigators and the International Breast Cancer Study Group (a division of ETOP IBCSG Partners Foundation). Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT. J Clin Oncol. 2023 Mar 1;41(7):1370-1375. doi: 10.1200/JCO.22.01065. Epub 2022 Dec 9. PubMed 36493334 ↗
  • Lu YS, Wong A, Kim HJ. Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women. Front Oncol. 2021 Sep 14;11:700722. doi: 10.3389/fonc.2021.700722. eCollection 2021. PubMed 34595110 ↗

Individual participant data

Plan to share: Yes — A complete publication plan will be taken into account, covering everything from the protocol to the dissemination of the results in scientific journals and scientific forums, such as specialized conferences.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: 2 years

Access criteria: Public access

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Apr 2025, 5 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 5 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2023
First posted
Dec 11, 2024
StartActual
Nov 15, 2024
Primary completionEst.
Apr 15, 2025
CompletionEst.
Dec 15, 2025
Last update
Dec 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06727487
Lead sponsor
Universidad Pontificia Comillas
Collaborators
Hospital General Universitario Gregorio Marañon, San Juan de Dios Foundation
Responsible party
Sponsor
First posted
Dec 11, 2024
Start date
Nov 15, 2024
Primary completion
Apr 15, 2025 (estimated)
Completion
Dec 15, 2025 (estimated)
Last update
Dec 11, 2024

Study contacts

Julio C de la Torre-Montero, Ph.D
Contact
juliodelatorre@comillas.edu
+34678581021
Maria Jesús Martínez Beltrán, Ph.D
Contact
mjesus.martinez@comillas.edu
Julio C de la Torre, Ph.D
study chair · Universidad Pontificia Comillas
Blanca Herrero López, MD
principal investigator · Hospital Universitario Gregorio Marañón
Soraya Casla Barrio, Ph.D
study director · Comillas Pontifical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion